Moreover, we have observed in other mouse models of malignancies (melanoma, lymphoma, neuroblastoma, breast, and kidney cancer) that IL2-based immunocytokines may show a minimal therapeutic activity on their own, but strongly synergise with other therapeutic regimens, leading to complete tumour eradication (Schliemann et al, 2009; Balza et al, 2010; Frey et al, 2010; Giavazzi et al, manuscript in preparation). This evidence concerns the gene IL2 and kidney cancer.